Celldex Therapeutics (CLDX) Other Operating Expenses (2010 - 2023)

Celldex Therapeutics' Other Operating Expenses history runs 14 years deep, the most recent figure standing at $12.5 million for Q4 2023.

• In Q4 2023, Other Operating Expenses rose 32794.74% year-over-year to $12.5 million; the TTM figure through Sep 2024 stood at $12.5 million (up 32794.74% YoY), while the FY2023 annual figure was -$12.5 million, down 281.16% from the prior year.
• Other Operating Expenses for Q4 2023 stood at $12.5 million, up from $38000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $12.5 million in Q4 2023, with the low at -$1.5 million in Q1 2019.
• The 5-year median for Other Operating Expenses is $121500.0 (2021), against an average of $1.6 million.
• The sharpest annual moves came in 2020 and 2023: Other Operating Expenses tumbled 133.11% in 2020, then surged 32794.74% in 2023.
• Celldex Therapeutics' Other Operating Expenses stood at -$318000.0 in 2019, then jumped by 105.66% to $18000.0 in 2020, then jumped by 1038.89% to $205000.0 in 2021, then sank by 81.46% to $38000.0 in 2022, then soared by 32794.74% to $12.5 million in 2023.
• Business Quant data shows CLDX's Other Operating Expenses at $12.5 million in Q4 2023, $38000.0 in Q4 2022, and $6.3 million in Q2 2022.